16 October 2023
16 October 2023
The Clinical Trials Arena team also review assets in oncology, autoimmune disorders and neurological disorder indications.
The most recent data adds to the initial announcement that the candidate met primary and secondary endpoints in the Phase III studies.
A decade-long continuous Ocrevus treatment allowed MS patients to walk unassisted, with many reporting no disability progression.
The heat therapy device demonstrated improved results in tear break up time compared with standard eyedrop treatment.
The completion of the Phase Ia/Ib trial may lead Adcentrx to a registrational trial with ADRX-0706.
A global Phase II study of the combined therapy was previously conducted in June 2020.
IMG-007 has shown a favourable safety profile, without any pyrexia or chill reports, in a Phase I study in healthy adults.
OSE-279 will be evaluated as a monotherapy in advanced solid tumours with two possible administration rates.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
